Eculizumab by Alexion Pharmaceuticals for Subarachnoid Hemorrhage: Likelihood of Approval

Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Subarachnoid Hemorrhage.

Related Keywords

Boston ,Massachusetts ,United States ,America ,Asia Pacific ,Eculizumab Soliris ,Alexion Pharmaceuticals ,Globaldata Pharmaceutical Intelligence Center ,Astrazeneca Plc ,Subarachnoid Hemorrhage ,Eculizumab Loa ,Phase Transition Success Rate Model ,Guillain Barre Syndrome ,Escherichia Coli ,Middle East ,North America ,Latin America ,Pharmaceutical Intelligence ,